When was Mariana Oncology founded?

Mariana Oncology was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Mariana Oncology located?

Mariana Oncology is headquartered in Watertown, United States.

Who is the current CEO of Mariana Oncology?

Simon Read of Mariana Oncology. They have also founded 1 company.

How many employees does Mariana Oncology have?

As of Sep 30, 2026, the latest employee count at Mariana Oncology is 98.

Is Mariana Oncology a funded company?

Mariana Oncology is a funded company, having raised a total of $250M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 01, 2021.

How much is Mariana Oncology worth?

The last known valuation of Mariana Oncology was $***** as of May 02, 2024.

When was the latest funding round of Mariana Oncology?

Mariana Oncology's latest funding was a $***** Series B round on Sep 07, 2023, with participation from 8 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.58B in funding in 2026 to date.

Where does Mariana Oncology rank among its competitors?

Mariana Oncology ranks 439th amongst 2573 active competitors, of which 866 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Mariana Oncology?

Mariana Oncology's top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Mariana Oncology - 2026 Company Profile, Team, Funding & Competitors

Q: Is Mariana Oncology an acquired company?

Mariana Oncology got acquired by Novartis on May 02, 2024.

Mariana Oncology is an acquired company based in Watertown (United States), founded in 2020 by Simon Read. It operates as a Developer of radiopharmaceuticals for solid tumors. Mariana Oncology has raised $250M in funding from investors like Atlas Venture, Access Industries and RA Capital Management, with last known valuation of $*****. The company has 2573 active competitors, including 866 funded and 634 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Tango Therapeutics and Elicio.

Company Details

Developer of radiopharmaceuticals for solid tumors. The company is pioneering a new class of targeted radiopharmaceuticals that are composed of rationally designed conjugates against biological targets, to deliver alpha and beta-emitting radionuclide payloads for oncological diseases.

Website: marianaoncology.com
Social
Email ID: *****@argotpartners.com

Key Metrics

Founded Year

2020

Location

Watertown, United States

Stage

Acquired

Total Funding

$250M in 2 rounds

Latest Funding Round

Series B, Sep 07, 2023, $*****

Last Known Valuation

$***** as on May 02, 2024

Investors

Atlas Venture & 8 more

Ranked

439^th among 2573 active competitors

Employee Count

98 as on Sep 30, 2026

Similar Companies

RayzeBio & 111 more

Exit Details

Acquired by Novartis (May 02, 2024)

View Mariana Oncology's full profile

Mariana Oncology is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
MARIANA ONCOLOGY, INC. CIN: 862522102 , United States, Active	Dec 31, 2020	-	73 (As on Dec 31, 2024)	-

Mariana Oncology got acquired by Novartis on May 02, 2024 at an acquisition amount of $*****.

Click here to take a look at Mariana Oncology's acquisition in detail

Mariana Oncology has raised a total funding of $250M over 2 rounds. Its first funding round was on Dec 01, 2021. Its latest funding round was a Series B round on Sep 07, 2023 for $*****. 8 investors participated in its latest round. Mariana Oncology has 9 institutional investors.

Here is the list of recent funding rounds of Mariana Oncology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 07, 2023	5054486	Series B	4964407	3165630	9070063	2494521
Dec 01, 2021	9351720	Series A	7594149	7972459	Atlas Venture & 2 more	6024244

Access funding benchmarks and valuations. Sign up today!

View details of Mariana Oncology's funding rounds and investors

The founders of Mariana Oncology is Simon Read. Simon Read is the CEO of Mariana Oncology.

Here are the details of Mariana Oncology's key team members:

Simon Read: Founder & CEO of Mariana Oncology.

View details of Mariana Oncology's Founder profiles and Board Members

Mariana Oncology's employee count trend

Mariana Oncology has 98 employees as of Sep 26. Here is Mariana Oncology's employee count trend over the years:

Employee count trend for Mariana Oncology

Uncover Mariana Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mariana Oncology include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of Mariana Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
7th	RayzeBio 2019, San Diego (United States), Acquired	R&D company focused on manufacturing of cancer drugs	$426M	Venrock, VenBio & 22 others	70/100
8th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
10th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
439th	Mariana Oncology 2020, Watertown (United States), Acquired	Developer of radiopharmaceuticals for solid tumors	$250M	Access Industries, Atlas Venture & 7 others	50/100